Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
J. Ng, L. Cai, L. Girard, O. Prall, N. Rajan, C. Khoo, A. Batrouney, A. Kersbergen, M. Christie, J. Minna, M. L. Burr, K. D. Sutherland
The paper reclassifies YAP1-expressing SCLC-Y as SMARCA4-deficient malignancies, showing they lack SCLC features and instead resemble SMARCA4-deficient tumors.
bioRxiv · Oct 9, 2022Cancer Biology
L. Cai, V. Sondhi, M. Zhu, E. Akbay, R. J. DeBerardinis, Y. Xie, J. Minna, G. Xiao, A. Gazdar
This study curates genes associated with NE transdifferentiation in SCLC and compares transcriptomic changes across multiple datasets to create a web tool for exploring NE transdifferentiation in SCLC and NBL.
bioRxiv · Aug 1, 2022 · PreprintCancer Biology
D. H. Huisman, D. Chatterjee, R. A. Svoboda, H. M. Vieira, A. S. Ireland, S. Skupa, J. W. Askew, D. E. Frodyma, L. Girard, K. W. Fisher, M. Kareta, J. Minna, T. G. Oliver, R. E. Lewis
This study shows KSR2 promotes self-renewal and clonogenicity in ASCL1-subtype SCLC by enhancing ERK signaling and tumor initiating capacity.
bioRxiv · Feb 11, 2022Cancer Biology
D. Bohan, H. Van Ert, N. Ruggio, K. J. Rogers, M. Baddredine, J. A. A. Briseno, R. A. Rojas Chavez, B. Gao, T. Stokowy, E. Christakou, D. Micklem, G. Gausdal, H. Haim, J. Minna, J. B. Lorens, W. Maury
This study identifies PS receptors, including AXL, as facilitators of SARS-CoV-2 infection by enhancing virus entry into human lung cells, suggesting AXL as a therapeutic target for COVID-19.
bioRxiv · Jun 15, 2021Microbiology
C. Bartolacci, C. Andreani, G. Dias do Vale, S. Berto, M. Melegari, A. C. Crouch, D. L. Baluya, G. Kemble, K. Hodges, J. Starrett, K. Politi, S. L. Starnes, D. Lorenzini, M. G. Raso, L. Solis Soto, , P. P. Scaglioni
This study identifies FASN as a therapeutic target in KRAS-mutant lung cancer by showing its role in lipid metabolism and ferroptosis induction.
bioRxiv · Mar 18, 2021Cancer Biology
J. Kim, F. Cai, B. Ko, C. Yang, H. M. Lee, N. Muhammad, K. Li, M. Haloul, W. Gu, B. Faubert, A. K. Kaushik, L. Cai, S. Kasiri, U. Marriam, K. Nham, , R. J. DeBerardinis
The paper identifies the hexosamine biosynthesis pathway as a metabolic vulnerability in KRAS/LKB1 mutant lung cancers and shows GFPT2 inhibition reduces tumor growth.
bioRxiv · Apr 13, 2020 · PreprintCancer Biology
P.-H. CHEN, L. Cai, C. Yang, J. Kim, B. Faubert, L. Boroughs, B. Ko, J. Sudderth, E. A. McMillan, L. Girard, M. Peyton, K. Huffman, M. D. Shields, D. Shames, H. S. Kim, , R. J. DeBerardinis
The paper quantifies metabolic features in NSCLC cell lines to explore associations between metabolism and other cell-autonomous processes.
bioRxiv · Mar 11, 2019Cancer Biology
L. Cai, S. Lin, Y. Zhou, L. Yang, B. Ci, Q. Zhou, D. Luo, B. Yao, H. Tang, J. Allen, K. Huffman, A. Gazdar, J. Heymach, I. Wistuba, G. Xiao, , Y. Xie
The paper constructs a lung cancer database with gene expression and clinical data from 6,700 patients and develops an open web portal for data exploration and analysis.
bioRxiv · Feb 24, 2018Cancer Biology